Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Allergy Therapeutics on £11.5 Million Placement and License Agreement

November 23, 2015

LONDON, November 23, 2015 — Covington represented Allergy Therapeutics, the AIM-listed specialty pharmaceutical company specializing in allergy vaccines, in the placement of ordinary shares raising approximately £11.5 million. The placement was conducted through an accelerated bookbuilding process with Panmure Gordon & Co acting as financial adviser, nominated adviser, and sole bookrunner.

Covington also represented Allergy Therapeutics in connection with a license agreement in respect of virus-like particle (VLP) technology. Allergy intends to use the license in the development of Polyvac Peanut, a new injectable vaccine immunotherapy treatment for peanut allergy sufferers, through to Phase I clinical trials.

The Covington team handling the placing was led by Simon Amies and Emma Heffernan, and included Kristian Wiggert (US securities), Guy Dingley (tax) and Morag Peberdy (IP). The team handling the licence consisted of Daniel Pavin, Lucinda Osborne, David Dennis, Jane Pinho and Winsome Cheung, with assistance from Adem Koyuncu and Sabine Stute on German matters.

Share this article: